Skip to main content
A

ApiJect

ApiJect develops a Blow-Fill-Seal technology platform that produces prefilled injectable medicines, enabling safe and efficient drug delivery. This approach reduces costs, simplifies administration for non-medical professionals, and enhances accessibility in various healthcare settings.

Stamford, United StatesFounded 2016787K+ followers
Updated 20 months ago

Funding

$111M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

BM
Funding rounds are not available yet.

Founders

Product

Problem

Traditional methods of delivering injectable medicines can be complex, costly, and require trained professionals, limiting accessibility and efficiency, especially in resource-constrained settings or during emergencies. Existing supply chains for injectable drugs can be inefficient and reliant on numerous raw materials and manufacturing steps.

Solution

ApiJect has developed a Blow-Fill-Seal (BFS) technology platform that produces prefilled, single-dose injectable medicines in a simplified and cost-effective manner. The BFS process aseptically fills a container, which is then combined with a pen needle hub, enabling easier administration by non-medical personnel or patients themselves. This approach aims to improve drug delivery by making it more affordable, accessible, and scalable, while also reducing the carbon footprint compared to traditional glass vials and syringes. The platform is designed for commercial pharmaceuticals, global health markets, and large-scale emergency response scenarios.

Target Audience

The primary target audience includes pharmaceutical companies, global health organizations, and government agencies involved in large-scale emergency response, seeking to improve the delivery of injectable medicines.

Features

  • Blow-Fill-Seal (BFS) technology for aseptic filling and sealing of single-dose injectable containers.
  • Integrated pen needle hub, similar to those used for insulin injections, for simplified administration.
  • Manufacturing process utilizing only two primary materials: medical-grade plastic resin and stainless steel rolls.
  • Customizable BFS prefilled injectors designed to be cost-competitive with single-dose vials.
  • Radically efficient supply chain requiring fewer raw materials and manufacturing steps.
  • Scalable manufacturing process capable of rapid ramp-up and adaptation to demand spikes.
  • Reduced carbon impact compared to glass vials and syringes.
This profile is AI-generated and may contain inaccuracies.